These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 33945995)
1. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy. Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995 [TBL] [Abstract][Full Text] [Related]
2. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9. Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492 [TBL] [Abstract][Full Text] [Related]
3. Replication efficiency of oncolytic vaccinia virus in cell cultures prognosticates the virulence and antitumor efficacy in mice. Chen NG; Yu YA; Zhang Q; Szalay AA J Transl Med; 2011 Sep; 9():164. PubMed ID: 21951588 [TBL] [Abstract][Full Text] [Related]
4. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9. Deng L; Fan J; Guo M; Huang B Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055 [TBL] [Abstract][Full Text] [Related]
5. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043 [TBL] [Abstract][Full Text] [Related]
6. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade. Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894 [TBL] [Abstract][Full Text] [Related]
7. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576 [TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT). Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644 [TBL] [Abstract][Full Text] [Related]
9. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation. Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846 [No Abstract] [Full Text] [Related]
13. Deciphering the Immunomodulatory Capacity of Oncolytic Vaccinia Virus to Enhance the Immune Response to Breast Cancer. Umer BA; Noyce RS; Franczak BC; Shenouda MM; Kelly RG; Favis NA; Desaulniers M; Baldwin TA; Hitt MM; Evans DH Cancer Immunol Res; 2020 May; 8(5):618-631. PubMed ID: 32127390 [TBL] [Abstract][Full Text] [Related]
14. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy. Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820 [TBL] [Abstract][Full Text] [Related]
15. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody. Patil SS; Gentschev I; Adelfinger M; Donat U; Hess M; Weibel S; Nolte I; Frentzen A; Szalay AA PLoS One; 2012; 7(10):e47472. PubMed ID: 23091626 [TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68. Ehrig K; Kilinc MO; Chen NG; Stritzker J; Buckel L; Zhang Q; Szalay AA J Transl Med; 2013 Mar; 11():79. PubMed ID: 23531320 [TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. Guse K; Sloniecka M; Diaconu I; Ottolino-Perry K; Tang N; Ng C; Le Boeuf F; Bell JC; McCart JA; Ristimäki A; Pesonen S; Cerullo V; Hemminki A J Virol; 2010 Jan; 84(2):856-66. PubMed ID: 19906926 [TBL] [Abstract][Full Text] [Related]
18. Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy. Adelfinger M; Bessler S; Frentzen A; Cecil A; Langbein-Laugwitz J; Gentschev I; Szalay AA Viruses; 2015 Jul; 7(7):4075-92. PubMed ID: 26205404 [TBL] [Abstract][Full Text] [Related]
19. Characterization of Oncolytic Vaccinia Virus Harboring the Human IFNB1 and CES2 Transgenes. Cho E; Islam SMBU; Jiang F; Park JE; Lee B; Kim ND; Hwang TH Cancer Res Treat; 2020 Jan; 52(1):309-319. PubMed ID: 31401821 [TBL] [Abstract][Full Text] [Related]